Ultragenyx Pharmaceutical (RARE) Non-Current Deferred Tax Liability (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $30.0 million in Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability changed 0.19% year-over-year to $30.0 million in Q1 2026; TTM through Mar 2026 was $30.0 million, a 0.19% change from a year earlier, with the FY2025 full-year figure at $30.0 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $30.0 million, roughly flat from $30.0 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for RARE reached as high as $33.3 million in Q1 2022 and fell as low as $30.0 million in Q4 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $31.0 million across 5 years, with a median of $30.1 million in 2023.
• Across the five-year window, Non-Current Deferred Tax Liability changed 0.0% in 2022 and decreased 5.08% in 2023, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $31.7 million in 2022, then dropped by 5.08% to $30.1 million in 2023, then slipped by 0.19% to $30.0 million in 2024, then changed by 0.0% to $30.0 million in 2025, then changed by 0.0% to $30.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $30.0 million in Q1 2026, $30.0 million in Q4 2025, and $30.1 million in Q3 2025.